BTX doses 1st patient | LCTX Message Board Posts

Lineage Cell Therapeutics

  LCTX website

  •  Special $399 Lifetime Membership offer ends soon:
    For anyone who may have missed the memo posted last week, in August of 2018 we offered a limited number of 1-yr options to purchase Lifetime Premium Memberships. Fewer than 2 dozen remain unexercised. Rather than allow them to expire worthless, we are making them available to serious takers on an exclusive
    first come, first served basis. CLICK HERE to lock in a lifetime of benefits & savings!

  • Not sure what all the "Premium Service" fuss is all about? 

    Watch this 2 minute video to find out.

  • Only 11 
    Lifetime Premium Memberships left

LCTX   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  204 of 206  at  7/12/2019 10:11:35 AM  by


BTX doses 1st patient

BioTime doses first patient with new formulation of OpRegen

Jul. 11, 2019 11:23 AM ET|About: BioTime, Inc. (BTX)|By: Douglas W. House, SA News Editor
The first patient has been dosed with BioTime's (BTX) new off-the-shelf Thaw-and-Inject formulation of OpRegen using the Orbit Subretinal Delivery System (Orbit SDS) in a Phase 1/2a clinical trial in patients with dry age-related macular degeneration.

The company says Orbit SDS enables the precise administration of OpRegen cells to the back of the eye, leading to improved dose control and greater safety.

OpRegen is a retinal pigment epithelium (RPE) transplant therapy consisting of RPE cells delivered under the retina via intraocular injection.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 45
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

About Us  �  Contact Us  �  Follow Us on Twitter  �  Members Directory  �  Help Center  �  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
� 2003-2018 All rights reserved. User Agreement
Financial Market Data provided by